Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model
Autore:
Lambright, ES; Kang, EH; Force, S; Lanuti, M; Caparrelli, D; Kaiser, LR; Albelda, SM; Molnar-Kimber, KL;
Indirizzi:
Univ Penn, Med Ctr, Dept Surg, Thorac Oncol Res Lab, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 l Res Lab, Philadelphia, PA 19104 USA Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 Dept Med, Philadelphia, PA 19104 USA Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 pt Pathol, Philadelphia, PA 19104 USA
Titolo Testata:
MOLECULAR THERAPY
fascicolo: 4, volume: 2, anno: 2000,
pagine: 387 - 393
SICI:
1525-0016(200010)2:4<387:EOPAIO>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
TO-CELL SPREAD; VIRUS TYPE-1; REPLICATION-COMPETENT; BRAIN-TUMORS; IMMUNOCOMPETENT MICE; ANTITUMOR IMMUNITY; MUTANT; VECTOR; CANCER; INFECTION;
Keywords:
HSV; cancer gene therapy; carrier cells; ovarian cancer; mesothelioma; oncolysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Molnar-Kimber, KL Dept Pathol & Lab Med, 409 Stellar Chance,422 Curie Blvd, Philadelphia, PA19104 USA Dept Pathol & Lab Med 409 Stellar Chance,422 Curie Blvd Philadelphia PA USA 19104
Citazione:
E.S. Lambright et al., "Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model", MOL THER, 2(4), 2000, pp. 387-393

Abstract

HSV-1716, a replicating nonneurovirulent herpes simplex virus type 1, has shown efficacy in treating multiple types of human tumors in immunodeficient mice. Since the majority of the human population has been previously exposed to herpes simplex virus, the efficacy of HSV-based oncolytic therapy was investigated in an immunocompetent animal tumor model. EJ-6-2-Bam-6a, a tumor cell line derived from h-ras-transformed murine fibroblast, exhibit a diffuse growth pattern in the peritoneal cavity of BALB/c mice and replicate HSV-1716 to titers observed in human tumors. An established intraperitoneal (ip) tumor model of EJ-6-2-Bam-6a in naive and HSV-immunized mice was used to evaluate the efficacy of single or multiple ip administrations of HSV-1716 (4 X 10(6) pfu/treatment) or of carrier cells, which are irradiated, ex vivo virally infected EJ-6-2-Bam-6a cells that can amplify the viral load in situ. All treated groups significantly prolonged survival versus mediacontrol with an approximately 40% long-term survival rate (cure) in the multiply treated, HSV-naive animals. Prior immunization of the mice with HSV did not significantly decrease the median survival of the single or multiply treated HSV-1716 or the carrier cell-treated groups. These studies support the development of replication-selective herpes virus mutants for use in localized intraperitoneal malignancies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 13:42:05